Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immorna (Hangzhou) Biotechnology Co. Ltd. is active in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is assigned to 1 distinct examiner and is located within 1 distinct art unit. This data points to a specific and narrow prosecution focus for the company's current filings. The concentration of 1 pending office action in a single unit indicates that the company is not currently managing a diverse docket at the USPTO.
The busiest examiner for the company is SHOMER, ISAAC, who is managing 1 pending office action. Because the total number of pending actions is also 1, this examiner is the only one currently reviewing the company's applications. Having 1 pending office action in 1 distinct art unit suggests that the company's current intellectual property strategy is focused on a single technical innovation. The reliance on 1 distinct examiner means that progress is tied to a single examination process.
Practitioners should focus on the specific requirements of SHOMER, ISAAC to advance the 1 busiest examiner pending case. The Biotechnology & Pharmaceuticals portfolio is currently managed through 1 distinct art unit, simplifying administrative tracking but centralizing prosecution risk. The outcome of the 1 pending office action will be the primary determinant of the company's immediate success in securing patent rights in this technical field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHOMER, ISAAC | 1 | 63.2% | +30.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263955 | IONIZABLE LIPID MOLECULE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PREPARATION OF LIPID NANOPARTICLE | SHOMER, ISAAC | 5d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263955 | IONIZABLE LIPID MOLECULE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PREPARATION OF LIPID NANOPARTICLE | SHOMER, ISAAC | 1612 | §103DP | Final Rejection | 5d overdue | Pending | Aug 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial